ELIGIBILITY AND REGISTRATION

Shareholders who wish to attend the Annual General Meeting must
• be listed in the share register maintained by Euroclear Sweden AB as of June 15, 2026,
• and notify Peptonic Medical AB in writing of their intention to attend no later than June 17, 2026, 
Färögatan 33, 164 53 Kista, or via email to info@peptonicmedical.se. The notice must 
include the full name, personal or corporate identification number, shareholding, address, 
telephone number, and, where applicable, information regarding proxies or assistants (maximum 
2). Where applicable, the registration must be accompanied by powers of attorney, certificates of registration, and other 
authorization documents.

NOMINEE-REGISTERED SHARES

Shareholders who have had their shares registered in the name of a nominee through a bank or securities firm must have 
their shares registered in their own name to be entitled to participate in the Annual General Meeting. Such registration may 
be temporary (so-called voting rights registration) and must be requested from the nominee in accordance with the nominee’s procedures. 
Voting rights registrations completed (registered with Euroclear Sweden AB) no later than June 17,
2026, will be taken into account when compiling the shareholder register.

PROXIES, ETC.

Shareholders represented by a proxy must issue a written power of attorney for the proxy, signed and 
dated by the shareholder. The term of validity of the power of attorney may be a maximum of five years if specifically stated. 
If no term of validity is specified, the power of attorney is valid for a maximum of one year. If the proxy is issued by a legal entity, 
a copy of the certificate of incorporation or equivalent for the legal entity must be attached. The original proxy 
and any certificate of incorporation should be submitted to the Company well in advance of the meeting. 
The proxy form will be available on the Company’s website, peptonicmedical.se, no later than two weeks 
before the meeting.

PROPOSED AGENDA

1. Opening of the meeting and election of a chairperson
2. Preparation and approval of the voting list
3. Election of one (1) or two (2) persons to verify the minutes
4. Determination of whether the meeting has been duly convened 
5. Approval of the agenda 
6. Address by the CEO 
7. Presentation of the annual report and audit reports, as well as the consolidated financial statements and 
the consolidated audit report
8. Resolutions regarding
a. adoption of the income statement and balance sheet, as well as the consolidated income statement and 
consolidated balance sheet
b. allocation of the Company’s net income in accordance with the adopted balance sheet, and 
c. discharge from liability to the Company for the members of the Board of Directors and the Chief Executive 
Officer
9. Determination of the number of Board members and alternate Board members 
10. Determination of fees for the Board and auditors
11. Election of Board members and any alternate Board members 
12. Election of auditors 
13. Resolution authorizing the Board of Directors to decide on new issues of shares, 
warrants, and/or convertible bonds
14. Resolution authorizing the Board of Directors to make minor adjustments to the resolutions adopted at the meeting
15. Adjournment of the meeting

PROPOSED RESOLUTIONS

Item 1 – Opening of the Meeting and Election of the Chairman of the Meeting 
The Nomination Committee proposes that Mark Falkner, Esq., of Eversheds Sutherland Avokatbyrå AB, or, 
in the event of his inability to attend, the person designated by the Nomination Committee in his stead, be elected as Chairman of the Meeting. 

Item 8b – Allocation of the Company’s net income according to the adopted 
balance sheet 
The Board of Directors proposes that no dividend be paid and that the net income be carried forward. 

Item 9 – Determination of the number of Board members and alternate Board members 
The Nomination Committee proposes that the Board consist of four (4) members without alternates. 

Item 10 – Determination of fees for the Board and the auditor 
The Nomination Committee proposes that the Board’s fees total SEK 850,000. The fee for 
the Board Chair shall be SEK 250,000 and for the other Board members SEK 200,000 
each. It is proposed that the auditor’s fees be paid in accordance with the approved invoice. 

Item 11 – Election of Board members and any alternate Board members 
The Nomination Committee will present its proposal for the Board via a press release as soon as 
possible.

Item 12 – Election of auditor
The Nomination Committee proposes the re-election of the auditing firm KPMG AB as the Company’s auditor for the period until 
the end of the next Annual General Meeting, with Dan Beitner as the principal auditor. 

Item 13 – Resolution to authorize the Board of Directors to decide on new issues of shares, warrants, and/or convertibles
The Board of Directors proposes that the Annual General Meeting authorize the Board of Directors to, on one or more occasions during the period 
until the next Annual General Meeting, resolve to increase the Company’s share capital within the limits of the
Articles of Association in effect at any given time regarding share capital and the number of shares. The authorization may be used to issue 
shares, warrants, and/or convertible loans. If the Board exercises this authorization, it may 
also do so with deviation from shareholders’ preemptive rights and/or with provisions regarding non-cash contributions 
or set-off. 
Issuances pursuant to this authorization shall be made on market terms. 

The Board of Directors shall have the right to determine the other terms and conditions for issuances pursuant to this authorization, as well as who shall have the right to subscribe for the securities issued. The reason the Board of Directors shall be able to decide on issuances witheviations from shareholders’ preemptive rights and/or with provisions regarding non-cash contributions or set-off is to enable the Company to raise capital, carry out strategically motivated collaborations or acquisitions, and facilitate the execution of issuances with the aim of strengthening the Company’s financial position. It is proposed that the Company’s CEO, or a person appointed by the Board, be authorized to make minor adjustments to this resolution that may be necessary in connection with registration with the Swedish Companies Registration Office and Euroclear Sweden AB.

Item 14 – Resolution to authorize the Board of Directors to make minor adjustments to the resolutions adopted at the Annual General Meeting

The Board of Directors proposes that the Annual General Meeting authorize the Board of Directors, the CEO, or whomever the Board of Directors otherwise designates to make such minor adjustments and clarifications to the resolutions adopted at the Annual General Meeting to the extent necessary for the registration of the resolutions.

OTHER

Majority Requirement

For a resolution under item 13, the resolution must be supported by shareholders representing at least two-thirds (2/3) of both the votes cast and the shares represented at the meeting.

Shareholders’ right to receive information

Pursuant to Chapter 7, Section 32 of the Swedish Companies Act, shareholders have the right to request information from the Board of Directors and the CEO regarding circumstances that may affect the assessment of a matter on the agenda and circumstances that may affect the assessment of the Company’s financial situation. The Board of Directors and the CEO shall provide such information if the Board deems that it can be done without causing material harm to the Company.

Processing of Personal Data

For information on how your personal data is processed in connection with the Annual General Meeting, see the privacy policy on Euroclear AB’s website, www.euroclear.com/dam/ESw/Legal/Integritetspolicy-bolagsstammor-svenska.pdf.

Documents

The notice of meeting includes the Board of Directors’ complete proposals for resolutions. The notice and documents pursuant to

the Swedish Companies Act will be made available to shareholders at the Company no later than two weeks prior to

the meeting and will be sent free of charge to shareholders who request them and provide their mailing address or

email address. The notice will also be published on the Company’s website and presented at the meeting.

Number of Shares and Votes

As of the date of this notice, the total number of shares and votes in the Company

is 20,724,567,314. The Company holds no treasury shares.

_____________________________

Stockholm, May

Peptonic Medical AB

The Board of Directors